Tags

Type your tag names separated by a space and hit enter

cannabidiol

General

Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.

cannabidiol

Pronunciation:
ka-na-bi-dye-ole

delta-9–tetrahydrocannabinol (THC)

Pronunciation:
del-ta nine tet-re-hye-dro-ka-na-bi-nole

Trade Name(s)

  • Sativex Canadian Tradename

Ther. Class.
analgesic adjuncts, therapeutic
antispasticity agents

Pharm. Class.
cannabinoids

Indications

  • Adjunct treatment of spasticity in adults with multiple sclerosis (MS) who have not responded to other therapies.
  • Analgesic adjunct in the management of neuropathic pain in patients with MS or advanced cancer who have not responded to opioids or other analgesics for severe pain.

Action

  • Acts on cannabinoid receptors located in pain pathways in the brain, spinal cord and peripheral nerve terminals.
  • Has analgesic and muscle relaxant properties.

Therapeutic Effect(s):

Decreased pain and spasticity.

Pharmacokinetics

Absorption: Buccal absorption is slower than inhalation.

Distribution: Highly lipid soluble, distributes and accumulates in fatty tissues. Cannabinoids enter breast milk in considerable amounts.

Metabolism and Excretion: Some first-pass hepatic metabolism occurs; highly metabolized by the CYP450 enzyme system. Metabolites can be stored in fatty tissues and re-released over time (up to weeks); one metabolite of THC is pharmacologically active (11–hydroxy-THC). Further metabolism occurs in renal and biliary systems.

Half-life: Bi-exponential half-lives with short initial phases of Cannabidiol– 1.4–1.8 hr; THC– 1.3–1.7 hr 11–hydroxy-THC– 1.9–2.1 hr; terminal elimination half-life of cannabinoids– 24–26 hr or more.

TIME/ACTION PROFILE (analgesic and antispasticity effects)

ROUTEONSETPEAK†DURATION
cannabidiol unknown1.6–2.8 hrup to 12 hr
THCunknown1.6–2.4 hrup to 12 hr
†Blood levels peak more quickly when administered under the tongue.

Contraindication/Precautions

Contraindicated in:

  • Allergy/hypersensitivity to cannabinoids, propylene glycol or peppermint oil;
  • Serious cardiovascular disease, including ischemic heart disease, arrhythmias, poorly controlled hypertension or severe heart failure;
  • History of schizophrenia/psychoses;
  • Patients with childbearing potential who are not using reliable contraception;
  • Sore/inflamed mucosa (may alter absorption);
  • OB: Pregnancy (avoid use);
  • Lactation: Avoid breast feeding (cannabinoids enter breast milk in considerable amounts);
  • Pedi: Safety and effectiveness not established.

Use Cautiously in:

  • Epilepsy/recurrent seizures;
  • Substance abuse;
  • Perioperative state (consider possible changes in cardiovascular status);
  • History of depression/suicide attempt or ideation;
  • Significant hepatic/renal impairment;
  • Rep: Women of reproductive potential (reliable contraception must be ensured);
  • Cancer patients with urinary tract pathology (↑ risk of urinary tract adverse reactions);
  • Geri: Use cautiously.

Adverse Reactions/Side Effects

CNS: dizziness, fatigue, confusion, depression, disorientation, drowsiness, euphoria, hallucinations, psychotic reactions, suicidal ideation, weakness

CV: hypertension, palpitations, tachycardia, postural hypotension

GI: appetite change, constipation, dry mouth, dysgeusia, mucosal/teeth discoloration, nausea (↑ in cancer patients), stomatitis

GU: urinary retention (↑ in cancer patients)

Local: application site irritation

Misc: physical dependence, psychological dependence

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

  • ↑ risk of CNS depression with other CNS depressants including alcohol, some antidepressants, some antihistamines, benzodiazepines, GABA inhibitors, sedative/hypnotics, opioids, and psychotropics/antipsychotics.
  • Cannabidiol inhibits the CYP450 enzyme system; may ↑ effects of amitriptyline, alfentanil, fentanyl and sufentanil.

Drug-Natural Products:

↑ risk of intoxication with other forms of cannibis.

Route/Dosage

Buccal: (Adults) Day 1– One spray in the morning and one in the evening; may ↑ by 1 spray/day on subsequent days. If unacceptable effects occur, temporarily discontinue and restart at a lower # of sprays/day or use longer intervals between sprays. Titrate to optimal maintenance dose (usual range 4–8 sprays/day, usually not more than 12 sprays/day; higher doses have been used/tolerated). Adjust dose to changes in patient condition.

Availability

Buccal spray contains ethanol (50% v/v), propylene glycol and peppermint oil: Each ml contains Cannabidiol– 25 mg and THC– 27 mg/ml. Delivers 100 microliter/spray, each spray provides cannabidiol 2.5 mg and THC 2.7 mg

Assessment

  • Assess patient's pain level before and after cannabidiol.

Potential Diagnoses

  • Acute pain
  • Chronic pain

Implementation

  • Prime pump before first use. Shake vial gently and remove protective cap. Hold vial in an upright position and press firmly and quickly on the actuator 2 or 3 times, until a fine spray appears. Point spray into a tissue, away from patient.
  • Administer one spray 2 times/day, in morning and in evening, on first day. Administer under tongue or in buccal area. Rotate sites in mouth to avoid irritation. Effects should be noticed in about 30 minutes. Do not spray the back of throat or into nose. After first day, increase dose by 1 spray every 24 hours, spacing doses evenly. No more than 12 doses should be used over a 24 hour period. Space each spray by at least 15 min.

Patient/Family Teaching

  • Caution patient to use medication as directed.
  • Instruct patient on correct spray technique. Instruct patient to rotate sites in the mouth between under the tongue and buccal locations.
  • Instruct patient to store unopened bottles in refrigerator. Do not freeze. Keep away from sources of heat such as direct sunlight or flames (product is flammable). Opened bottles may be stored at room temperature. Keep out of reach of children.
  • Inform patient that any unused contents should be discarded after 28 days. Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Consult pharmacist how to dispose of expired or unneeded medication.
  • Caution patient to avoid alcohol while taking cannabidiol.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Decrease in pain.
  • Decrease in muscle spasticity.
cannabidiol is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.

Citation

Quiring, Courtney, et al. "Cannabidiol." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109848/2/cannabidiol.
Quiring C, Sanoski CA, Vallerand AH. Cannabidiol. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109848/2/cannabidiol. Accessed July 23, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Cannabidiol. In Davis's Drug Guide. Available from https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109848/2/cannabidiol
Quiring C, Sanoski CA, Vallerand AH. Cannabidiol [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 July 23]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109848/2/cannabidiol.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - cannabidiol ID - 109848 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109848/2/cannabidiol PB - F.A. Davis Company ET - 16 DB - Nursing Central DP - Unbound Medicine ER -